We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Gilead Sciences (GILD - Free Report) is expected to reveal quarterly earnings of $1.58 per share, indicating a decline of 31% compared to the year-ago period. Analysts forecast revenues of $6.99 billion, representing a decrease of 0.9% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 2.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Gilead metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Revenues- Royalty contract and other revenues' will reach $49.47 million. The estimate indicates a year-over-year change of -11.7%.
The average prediction of analysts places 'Revenues- Product sales' at $6.96 billion. The estimate points to a change of -0.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Product Sales- Descovy- Total' should come in at $525.37 million. The estimate points to a change of +2.8% from the year-ago quarter.
The consensus estimate for 'Product Sales- Trodelvy- Total' stands at $354.13 million. The estimate indicates a year-over-year change of +25.1%.
It is projected by analysts that the 'Product Sales- Genvoya- U.S' will reach $374.53 million. The estimate suggests a change of -13.5% year over year.
Analysts expect 'Product Sales- Other Product- Other- U.S.' to come in at $40.89 million. The estimate suggests a change of +20.3% year over year.
The collective assessment of analysts points to an estimated 'Product Sales- Vemlidy- U.S' of $116.80 million. The estimate points to a change of +4.3% from the year-ago quarter.
The combined assessment of analysts suggests that 'Product Sales- AmBisome- U.S.' will likely reach $11.96 million. The estimate indicates a year-over-year change of -0.3%.
Analysts forecast 'Product Sales- Total HIV- US' to reach $3.97 billion. The estimate suggests a change of +4.4% year over year.
Based on the collective assessment of analysts, 'Product Sales- Other HIV- U.S' should arrive at $29.13 million. The estimate indicates a year-over-year change of +191.3%.
Analysts' assessment points toward 'Product Sales- Veklury- U.S' reaching $131.64 million. The estimate points to a change of -49% from the year-ago quarter.
Analysts predict that the 'Product Sales- Trodelvy- U. S' will reach $252.96 million. The estimate indicates a change of +25.9% from the prior-year quarter.
Over the past month, Gilead shares have recorded returns of +5.5% versus the Zacks S&P 500 composite's -1% change. Based on its Zacks Rank #3 (Hold), GILD will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
The upcoming report from Gilead Sciences (GILD - Free Report) is expected to reveal quarterly earnings of $1.58 per share, indicating a decline of 31% compared to the year-ago period. Analysts forecast revenues of $6.99 billion, representing a decrease of 0.9% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 2.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Gilead metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Revenues- Royalty contract and other revenues' will reach $49.47 million. The estimate indicates a year-over-year change of -11.7%.
The average prediction of analysts places 'Revenues- Product sales' at $6.96 billion. The estimate points to a change of -0.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Product Sales- Descovy- Total' should come in at $525.37 million. The estimate points to a change of +2.8% from the year-ago quarter.
The consensus estimate for 'Product Sales- Trodelvy- Total' stands at $354.13 million. The estimate indicates a year-over-year change of +25.1%.
It is projected by analysts that the 'Product Sales- Genvoya- U.S' will reach $374.53 million. The estimate suggests a change of -13.5% year over year.
Analysts expect 'Product Sales- Other Product- Other- U.S.' to come in at $40.89 million. The estimate suggests a change of +20.3% year over year.
The collective assessment of analysts points to an estimated 'Product Sales- Vemlidy- U.S' of $116.80 million. The estimate points to a change of +4.3% from the year-ago quarter.
The combined assessment of analysts suggests that 'Product Sales- AmBisome- U.S.' will likely reach $11.96 million. The estimate indicates a year-over-year change of -0.3%.
Analysts forecast 'Product Sales- Total HIV- US' to reach $3.97 billion. The estimate suggests a change of +4.4% year over year.
Based on the collective assessment of analysts, 'Product Sales- Other HIV- U.S' should arrive at $29.13 million. The estimate indicates a year-over-year change of +191.3%.
Analysts' assessment points toward 'Product Sales- Veklury- U.S' reaching $131.64 million. The estimate points to a change of -49% from the year-ago quarter.
Analysts predict that the 'Product Sales- Trodelvy- U. S' will reach $252.96 million. The estimate indicates a change of +25.9% from the prior-year quarter.
View all Key Company Metrics for Gilead here>>>
Over the past month, Gilead shares have recorded returns of +5.5% versus the Zacks S&P 500 composite's -1% change. Based on its Zacks Rank #3 (Hold), GILD will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>